安罗替尼联合培美曲塞对晚期非鳞非小细胞肺癌JAK/STAT3信号传导通路的影响

Effect of Anrotinib Combined with Pemetrexed on JAK/STAT3 Signaling Pathway in Advanced Non-squamous Non-small-cell Lung Cancer

目的研究安罗替尼联合培美曲塞对晚期非鳞非小细胞肺癌JAK/STAT3信号传导通路的影响。方法选取82例晚期非鳞非小细胞肺癌患者为此次试验对象,随机分成2组。对照组(41例)术后接受培美曲塞治疗,实验组(41例)在此基础上联合安罗替尼治疗。对比两组患者治疗前后Janus激酶(JAK)、转录激活因子3(STAT3)表达情况;对比两组患者临床疗效和化疗不良反应。结果治疗后两组患者JAK、STAT3表达均明显降低,且相比于对照组,实验组显著更低(P<0.05)。与对照组总有效率[70.73%(29/41)]相比,实验组总有效率[95.12%(39/41)]显著更高(P<0.05)。对照组不良反应发生率[34.14%(14/41)]与实验组不良反应发生率[21.95%(9/41)]相比,差异无统计学意义(P>0.05)。结论对于晚期非鳞非小细胞肺癌患者,在培美曲塞基础上联合安罗替尼治疗,可有效抑制JAK/STAT3信号传导通路活性,临床疗效较高,并且不会增加不良反应的发生。

Objective To investigate effect of anrotinib combined with pemetrexed on janus kinase/signal transducer and activator of transcription(JAK-STAT)signaling pathway in advanced non-squamous non-small-cell lung cancer.Methods 82 patients with advanced non squamous non-small cell lung cancer were randomly divided into 2 groups.The control group(41 cases)was treated with pemetrexed after operation,while the experimental group(41 cases)was treated with anlotinib on this basis.Then the expression levels of JAK and STAT3 were recorded,and the clinical outcomes and adverse reactions during chemotherapy were compared between the 2 groups.Results After treatment,the expression levels of JAK and STAT3 were significantly decreased in both groups,and the expression in the experimental group was obvious lower than the control group(P<0.05).Compared with the total effective rate of the control group[70.73%(29/41)],the total effective rate of the experimental group[95.12%(39/41)]was significantly higher(P<0.05);There was no significant difference in the incidence of adverse reactions between the control group[34.14%(14/41)]and the experimental group[21.95%(9/41)](P>0.05).Conclusion Application of anrotinib based on pemetrexed therapy in the treatment of advanced non-squamous non-small-cell lung cancer after surgery can effectively inhibit the JAK/STAT3 signaling pathway without increasing adverse reactions.